Our Specialty Ingredients segment is operating in 15 highly regulated anti-microbial fields of application and providing 25 technology platforms – from single ingredient to turnkey solutions, fully serviced with application technology and regulatory support. These offerings represent the most-comprehensive portfolio of anti-microbial solutions in the market.
Lonza will continue to leverage this unique anti-microbial expertise and offer products and solutions that significantly improve consumer and resource protection from harmful biological risks.
Discover Lonza Specialty Ingredients segment as operated in 2017:
As of 1 January 2018, the Specialty Ingredients segment began operating in three distinctive units: a Consumer Health Division, a Consumer & Resources Protection Division and a Water Care Business Unit.
The former Consumer Health and Nutrition business of Capsugel has been integrated within the existing Consumer Health and Nutrition business of Lonza’s Specialty Ingredients segment, and together they have formed the new Consumer Health and Nutrition Business Unit. Together with the Consumer Product Ingredients Business Unit, they have formed the new Consumer Health Division. Coatings and Composites and Agro Ingredients are continuing to operate in their current structures under the new umbrella of a Consumer & Resources Protection Division.
Specialty Ingredients Overview 2017
Specialty Ingredients delivered strong results with growth drivers along and beyond the healthcare continuum.
The segment (Lonza standalone) posted sustained positive performance again this year with a sales increase of 5.2% (4.8% in constant exchange rates) to CHF 2.4 billion during 2017. CORE EBIT grew by 10.2% year-over-year to CHF 367 million with further improved margins. This strong performance was driven not only by Consumer Care businesses, but also by the further value creation achieved in the Coatings and Composites business, which includes Wood Protection, and in the Agro Ingredients business.
Specialty Ingredients Financial Summary 1,2
|million CHF||2017||Change in %||2016|
|CORE EBIT margin in %||15.3||14.6|
|CORE EBITDA 3||466||9.4||426|
|CORE EBITDA margin in %||19.4||18.7|